07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

AIKO-150: Phase I data

A dose-escalating Phase I trial in 5 healthy volunteers administered morphine showed that 1-20 mg doses of AIKO-150 selectively improved bowel motility without interfering with opioid-induced pain relief. No significant adverse effects were observed. Aiko...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Company News

Aiko Biotechnology management update

Aiko Biotechnology Inc. , Portland, Maine   Business: Neurology, Gastrointestinal   Hired: Jim New as CEO, formerly president and CEO of LifeCycle Pharma A/S  ...
00:56 , Sep 30, 2010 |  BC Extra  |  Company News

Aiko names New CEO

Neurology and gastrointestinal company Aiko Biotechnology Inc. (Portland, Maine) hired Jim New as its first CEO. New was formerly president and CEO of LifeCycle Pharma A/S (CSE:LCP)....